On June 27, Mr. Nakamura, Account Director of Dentsu Creative(Japan) China, Mr. Watanabe, General Manager of Kokuyo (Japan Yuyu Office) Co., LTD. Shenzhen Branch, and Mr. Zhang Fan, Sales Department of Shinchi Co., LTD., Wang Jiannan, general manager of Shenzhen Faith Investment Management Co., LTD., Chen Lifi, Assistant general manager of Shenzhen Yawei Information Technology Group Co., LTD., Yang Jun, general manager of Shenzhen Yawei Information Technology Group Co., LTD., Cheng Bing, operation manager of China-Canada Innovation Center, Chen Qi, general manager of Shenzhen Thinking Feeler Information Consulting Co., LTD., visited Shenzhen Cell Valley Biomedicine Co., LTD. Chairman of Shenzhen Cell Valley Professor Shi Yuanyuan, chief scientist Professor Wang Jianxun, Deputy general manager Tang Xiaomeng, General Office director Luan Zhishi, Chairman assistant Wei Zheng, Sales director Yang Bolui, Sales director Yan Chengkun, marketing director Gulina Ge Halimu warmly received, and the two sides had a discussion and exchange on the direction of cooperation planned between China and Japan.

First of all, Luan Zhishi, director of the comprehensive Office, led the Chinese and Japanese entrepreneurs to visit the company's wisdom exhibition hall, and made a preliminary explanation of the company's corporate vision, founder team, enterprise development history, CAR-T history history, service platform construction, and then held a symposium.

At the symposium, Chairman Shi Yuanyuan first warmly welcomed the arrival of Chinese and Japanese entrepreneurs, and then Luan Zhishi, director of the comprehensive Office, introduced in Japanese the current situation and development trend of Sino-Japanese cell therapy, the core products and services of Shenzhen Cell Valley, technical advantages, comprehensive strength, development strategy, etc., and then the two sides carried out in-depth discussions and exchanges. Chairman Shi Yuanyuan said that in terms of the research and development layout of innovative technologies, China and Japan have their own strengths, such as Japan in the field of stem cell (such as IPSc: induced pluripotent stem cell) technology, and in the field of anti-aging and anti-aging has achieved remarkable results, while China has made breakthroughs in CAR-T, CAR-NK and other cell therapy technology. In the future, it is expected that the pharmaceutical enterprises of China and Japan will strengthen the linkage, accelerate the landing of innovative products and cutting-edge therapies, and benefit more patients; At the same time, we hope to fully integrate the cutting-edge technology of China and Japan in the field of cell therapy through the construction of the resource platform, achieve complementary advantages in policy, talent, capital and technology, and carry out in-depth cooperation in the field of cell and gene therapy, join hands with the high-quality resources of the Chinese and Japanese pharmaceutical industry, actively carry out cooperation, and provide patients with high-quality medical products and services between China and Japan, and achieve a win-win situation.

The successful holding of this Sino-Japanese entrepreneur exchange event will effectively promote the cooperation between Shenzhen Cell Valley and Japanese enterprises in the cell and gene therapy industry. Shenzhen Cell Valley will give full play to its advantages in the technology and platform for the industrial production of viral vectors, and cooperate with famous Japanese enterprises to promote the entry of cell and gene therapy products into the Japanese market and promote the high-quality development of this field.